NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of supplying vital pharmaceutical intermediates, and Gefitinib, with CAS number 184475-35-2, stands out as a critical component in the advancement of targeted cancer therapies. Its primary use is in the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), where it has demonstrated significant efficacy. As a leading provider, we ensure the highest quality for this essential compound, supporting the pharmaceutical industry's critical work.

The therapeutic power of Gefitinib lies in its precise mechanism of action: it functions as a protein kinase inhibitor. By targeting specific signaling pathways that drive cancer cell proliferation, particularly those involving EGFR mutations, Gefitinib offers a more personalized and effective treatment strategy. This targeted approach has revolutionized the management of certain NSCLC subtypes, providing hope and improved outcomes for patients.

As a pharmaceutical intermediate, Gefitinib CAS 184475-35-2 is synthesized to exacting standards. Its chemical identity includes being known as N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, with a molecular formula of C22H24ClFN4O3 and a molecular weight of 446.902. Typically appearing as a white to beige powder with a melting point around 119-120°C, its consistent quality is essential for reliable drug manufacturing. NINGBO INNO PHARMCHEM CO.,LTD. upholds rigorous quality control to guarantee the purity and stability of our Gefitinib intermediate.

The clinical application of Gefitinib therapy necessitates an understanding of its profile, including potential side effects. While effective, it has been observed to cause transient elevations in liver enzymes, and rarely, acute liver injury. This emphasizes the importance of careful patient selection and monitoring. For manufacturers, it also highlights the critical need for high-purity Gefitinib pharmaceutical intermediate, supplied by trusted partners like NINGBO INNO PHARMCHEM CO.,LTD., to minimize risks and maximize therapeutic benefits.

In conclusion, Gefitinib CAS 184475-35-2 is a pivotal compound in the ongoing battle against lung cancer. Its role as a protein kinase inhibitor makes it indispensable for targeted therapy development. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying this crucial pharmaceutical intermediate, thereby contributing to the advancement of medical science and the improvement of patient lives. Our dedication to quality and reliability ensures that we remain a key partner for pharmaceutical companies worldwide.